GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » BioForce Nanosciences Holdings Inc (OTCPK:BFNH) » Definitions » Debt-to-EBITDA

BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Debt-to-EBITDA : 0.00 (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is BioForce Nanosciences Holdings Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioForce Nanosciences Holdings's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. BioForce Nanosciences Holdings's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.00 Mil. BioForce Nanosciences Holdings's annualized EBITDA for the quarter that ended in Dec. 2023 was $-0.46 Mil. BioForce Nanosciences Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for BioForce Nanosciences Holdings's Debt-to-EBITDA or its related term are showing as below:

BFNH's Debt-to-EBITDA is not ranked *
in the Consumer Packaged Goods industry.
Industry Median: 2.145
* Ranked among companies with meaningful Debt-to-EBITDA only.

BioForce Nanosciences Holdings Debt-to-EBITDA Historical Data

The historical data trend for BioForce Nanosciences Holdings's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioForce Nanosciences Holdings Debt-to-EBITDA Chart

BioForce Nanosciences Holdings Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioForce Nanosciences Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioForce Nanosciences Holdings's Debt-to-EBITDA

For the Packaged Foods subindustry, BioForce Nanosciences Holdings's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioForce Nanosciences Holdings's Debt-to-EBITDA Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, BioForce Nanosciences Holdings's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where BioForce Nanosciences Holdings's Debt-to-EBITDA falls into.



BioForce Nanosciences Holdings Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

BioForce Nanosciences Holdings's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.472
=0.00

BioForce Nanosciences Holdings's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -0.456
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


BioForce Nanosciences Holdings  (OTCPK:BFNH) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


BioForce Nanosciences Holdings Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of BioForce Nanosciences Holdings's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Business Description

Traded in Other Exchanges
N/A
Address
2020 General Booth Boulevard, Suite 230, Virginia Beach, VA, USA, 23454
BioForce Nanosciences Holdings Inc is a provider of natural vitamins, minerals, and other nutritional supplements, powders, and beverages. It markets its products through social media and telemarketing.
Executives
Richard Kaiser Kaiser director, 10 percent owner, officer: Secretary/Acting CFO 3419 VIRGINIA BEACH BLVD, UNIT 252, VIRGINIA BEACH VA 23452
Merle Ferguson director, 10 percent owner, officer: CEO/President/Treasurer 2020 GENERAL BOOTH BLVD., SUITE 230, VIRGINIA BEACH VA 23454
Susan Donohue 10 percent owner 19001 S. RICHFIELD AVE, #102, GREEN VALLEY AZ 85614
Michael D Dunham director 12000 W PARK PL, EFFECTIVE MANAGEMENT SYSTEMS INC, MILWAUKEE WI 53224
Gregory D Brown officer: Chief Financial Officer BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE - SUITE 101, AMES IA 50010-8098
Kerry M Frey officer: Chief Operating Officer BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE - SUITE 101, AMES IA 50010
Eric Henderson director, 10 percent owner BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE, SUITE 101, AMES IA 50010
Lawrence Marshall Gold director 830 MENLO AVENUE, SUITE 100, MENLO PARK CA 94025
Jean-jacques Sunier director BIOFORCE NANOSCIENCES HOLDINGS, INC., 1615 GOLDEN ASPEN DRIVE, SUITE 101, AMES IA 50010
Societe Generale Asset Management Alternative Investments 10 percent owner 170, PLACE HENRI REGNAULT, LADEFENSE, PARIS I0 92043
Ed Cowle 10 percent owner 6 EAST 45TH ST., SUITE 1000, NEW YORK NY 10017
H Deworth Williams 10 percent owner 2681 EAST PARLEYS WAY, SUITE #204, SALT LAKE CITY UT 84109
Carter Robert P Iii 10 percent owner 25 RADCLIFFE DRIVE, VOORHEES NJ 08043
Harvey N Kaye 10 percent owner 190 NW SPANISH RIVER BLVD., SUITE 101, BOCA RATON FL 33431

BioForce Nanosciences Holdings (BioForce Nanosciences Holdings) Headlines

No Headlines